Companion Diagnostics in Driver's Seat
FDA's Draft Guidance Changes Game in Early Alzheimer's
By Marie Powers
Friday, March 15, 2013
Last month, the FDA's Center for Drug Evaluation and Research issued a draft guidance on the development of drugs in early stage Alzheimer's disease (AD). Intended as a conversation starter, the draft lays out a potential approach to select subjects with early AD and those at risk of developing the disease for enrollment into clinical trials.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.